Form 4: Labcorp SVP Granted Stock Options, RSUs

Labcorp Holdings Inc.'s SVP and Chief Accounting Officer, Peter J. Wilkinson, was granted 1,300 non-qualified stock options and 440 restricted stock units.

Summary

• Peter J. Wilkinson, SVP, Chief Accounting Officer of Labcorp Holdings Inc., acquired 1,300 non-qualified stock options and 440 Restricted Stock Units (RSUs).
• The stock options have an exercise price of $284.5 per share and vest in three equal annual installments starting February 10, 2027, expiring on February 9, 2036.
• The RSUs represent the contingent right to receive one share of Common Stock each and also vest in three equal annual installments beginning February 10, 2027.
• Following this transaction, Mr. Wilkinson beneficially owns an aggregate of 2,664 Restricted Stock Units.
• Both grants were made on February 10, 2026, under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting ongoing executive alignment with shareholder interests through standard equity compensation practices.

Positives

• The grant of stock options and restricted stock units aligns management's interests with shareholder value creation.
• The vesting schedule encourages long-term commitment from a key executive.

Future Outlook

The grants are part of the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan, indicating a continued strategy of using equity-based compensation to incentivize executives.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as stock options and restricted stock units, is a standard practice across the healthcare and diagnostics industry to attract, retain, and motivate key executives. This aligns Labcorp with common industry compensation structures.

Comparison to Industry Standards

• The use of multi-year vesting schedules for both stock options and RSUs is a common practice in the S&P 500, including peers like Quest Diagnostics (DGX) and other large healthcare service providers, to promote long-term executive retention and performance.
• The grant size for a Senior Vice President and Chief Accounting Officer is generally in line with compensation packages observed for similar roles at companies of comparable market capitalization within the diagnostics and laboratory services sector.

Related Party Transactions

• The transaction involves an equity grant to a senior executive, which is a common form of related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: Potential positive impact as executive compensation is tied to company performance, aligning interests.
• Employees: No direct impact on general employees, but reflects the company's compensation strategy for senior leadership.

Next Steps

• The stock options and Restricted Stock Units will begin vesting in three equal annual installments starting February 10, 2027.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a senior executive, which is a standard practice for public companies. It does not present new information that would fundamentally alter the investment thesis for Labcorp Holdings Inc., thus a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.

Keywords

Labcorp Holdings Inc., LH, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Executive Compensation, Peter J. Wilkinson, SVP Chief Accounting Officer